Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DNDN Short Interest Rises to 32M shares
http://www.nasdaq.com/asp/quotes_full.asp?kind=shortint&symbol=DNDN&selected=DNDN
Settlement Date ShortInterest Avg DailyVolume Daysto Cover
Dec. 31, 2007 32,757,569 3,094,744 10.58
Dec. 14, 2007 29,556,485 6,398,078 4.62
Nov. 30, 2007 29,628,330 2,105,593 14.07
Nov. 15, 2007 29,991,240 1,646,903 18.21
Oct. 31, 2007 29,582,444 2,014,874 14.68
Oct. 15, 2007 29,666,561 3,324,599 8.92
Sep. 28, 2007 28,712,317 2,584,558 11.11
Sep. 14, 2007 32,170,022 4,287,681 7.50
Aug. 15, 2007 36,029,103 4,134,767 8.71
Jul. 13, 2007 42,339,655 8,288,430 5.11
Jun. 15, 2007 40,847,280 20,081,558 2.03
May 15, 2007 41,662,926 32,227,947 1.29
Provenge fight - new LA Times article
http://www.latimes.com/features/health/la-he-prostate31dec31,1,5939875.story?coll=la-headlines-health
"FDA flip-flop mobilizes prostate cancer patients to activism"
After fast-tracking the end-stage cancer medication Provenge, the agency changed its mind.
By Shari Roan, Los Angeles Times Staff Writer
December 31, 2007
Best Wishes to PC Patients & Provenge in 2008.
What can DNDN shareholders & PC patients say. We got screwed in 2007, PC patients continued to suffer on chemo with no options, 1/3 of them died that could have responded to Provenge based on cold hard science fact.
If you had any doubt in the sheer evil of Wall Street Greed, the corrupting effect of Heavy Short Interest (sarcasm) and Multi-billion dollar industry (chemo) status quo, the events that occurred after 3/29/07 put that notion to rest.
I didn't expect Provenge to get the thumbs up on 3/29/07. But I was overjoyed when it did. I post here only because I think Walldiver the moderator is a man of integrity. The pumpers & bashers &daytraders & stock players on the other boards can go to heck. Sure I am going to profit off a cancer treatment. But I sure am not going to profit off of keeping dying men from getting it.
2008 holds great hope. Let's accentuate the positive. Provenge is:
- the first cancer immunotherapy to be recommended for approval (13-4!!!)
- Already has a safety database of over 500 patients (before 9902B) that shows, as the panel said 17-0, that it's the safest and least-toxic option available to PC patients
- Congressional hearing on the crime that occurred on 5/8/07 to happen in early 2008.
- Dendreon appears quite hopeful that the interim look at 2008 has the potential to get Provenge approved, and they have a solid "contract" with the FDA that should eliminate all gray area influence on approval, regardless of any backlash from the hearings, assuming those FDA employees are still allowed to work there by the time the interim comes out
- Provenge visibility has been elevated throughout the prostate cancer patient/doctor/advocate community due to this scandal. Why this didn't occur between 3/29/07 and 5/8/07 is a tragedy.
Good luck, DNDN shareholders. Don't let the bastards shake you out and grind you down. Hold long, hold strong, and donate from your profits to a cancer charity.
10-Q out: (0.23) beats (0.26) est
they are keeping expenses in check, R&D spending down.
walldiver: Pls Respond to Motley Fool's Lies
Lawler is at it again.
Now he's claiming that 3 year survival wasn't pre-specified.
re:Buyins.net has day to day running short sales counts
No, they don't.
re:short count
that's some fascinating spam bs, zebra, because short interest is only disclosed once a month and that update is around the 24th-26th of every month.
don't give a $hit about intraday trading. I've been long DNDN since late 2003, and have been buying every month since. I think this company should be valued above $10B on Provenge revenues alone, and will eventually go above $20B as trp-p8, the "drug" that will take Dendreon to Genentech levels, has its coming out party.
Not to mention Neuvenge in the interim....
This company has been the victim of a very illegal stock manipulation scheme by several hedge funds and a couple of very large prime brokers since Nov 2004.
And they're going to pay for it....
SEC views downward manipulation as a trading strategy that must be protected by all means necessary for their future employers.
it's as relevant as a double-secret triple reiteration of $1.50 by aschoff.
By the way, Provenge has been blessed since CBER got the football. Why some analysts and shorts insist on making fools of themselves since that happened is a question only they can answer.
Medicare Doc Mentions Provenge
Attachment #07.89
Page 11
Request to establish a code for sipuleucel-T, trade name: Provenge®. Recommended
Language: JXXXX “Sipuleucel-T, 250 mL”
Neeham note on approval not on wires...
Imagine that.
DJ only likes to put the negative bs from their hedgie friends on your ticker.
http://www1.investorvillage.com/smbd.asp?mb=971&pt=msg&mn=95022
Duncan just said he believes approval to happen
cites FDA panel.
Bloomberg captions mention $1B rev potential
Targets high 20's.
Bloomberg reporter claims Paul Allen sold >1M DNDN (WTF? maybe years ago)
Duncan about to talk DNDN on Bloomberg EOM
<alternative? Taxotere? Nothing?>
Studies show that 50% of these men refuse to suffer Taxotere...for them there is no alternative without Provenge...
Bloomberg just hammered DNDN again on TV
Indian chick reading script from Timmerman piece, but cherry picked negative side of Miller's comments.
Obscene.
Good thing I know Provenge has been slated to be approved since the day we all found out CBER was going to do the review, lol...
DNDN added to HealthShares Index
note the irony of the email address at the end....
HealthShares(TM) Announces Changes to the HealthShares(TM) Dermatology & Wound Care, Emerging Cancer, and Composite Indexes
Last update: 4/26/2007 5:56:00 PM
NEW YORK, April 26, 2007 /PRNewswire via COMTEX/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the calculating agent for the HealthShares(TM) Indexes, that effective at the opening of trading on Monday April 30, 2007, Integra Life Sciences (IART) will replace Merck Serono (SRA) in the HealthShares(TM) Dermatology and Wound Care Index; and XOMA Ltd. (XOMA) will replace Merck Serono in the HealthShares(TM) Emerging Cancer Index. Additionally, Dendreon Corp. (DNDN) will replace Merck Serono in the HealthShares(TM) Composite Index. The remaining public interest in Merck Serono was acquired by its parent company Merck KGaA.
Companies included in the Dermatology and Wound Care Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of skin disorders by topical or systemic means.
Companies included in the Emerging Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers.
About HealthShares(TM)
XShares Advisors LLC, a financial services company based in New York, is the creator of the HealthShares(TM) family of Exchange Traded Funds (ETFs). HealthShares(TM) ETFs are organized into therapeutic 'Verticals' and represent specific areas of the healthcare, life science and biotechnology industries. Each Vertical addresses a distinct sub-segment of healthcare, such as the diagnosis and treatment of specific therapeutic areas (e.g. cardiology, cancer, infectious disease, etc.) and the development of medical devices (e.g. orthopedic repair, cardio devices, etc.). Each ETF tracks an index of 22-25 stocks and offers institutional and individual investors a more precise financial instrument that leverages the potential of healthcare investing while mitigating the risks of single stock picking. For more information, visit the company's website at: .
About XShares
XShares Advisors LLC, a subsidiary of XShares Group LLC, is a registered investment 2 advisor that provides investment advisory services to Exchange Traded Funds. XShares also partners with major institutions and index providers seeking to bring innovative Exchange Traded Funds to market using its administrative platform. In addition, XShares creates and licenses distinctive intellectual property for its ETFs, developing products that allow for innovative trading strategies and alternative investments for the financial community. For more information, visit the company's website at .
An Investor should consider the fund's investment objective, risks, charges and expenses carefully before investing. For this and more complete information about the fund call 800.925.2870 or visit the website for a prospectus. Please read the prospectus carefully before investing.
There are risks involved with investing in ETFs including possible loss of money. HealthShares(TM) are not actively managed and are subject to risks similar to stocks, including those related to short selling and margin maintenance. HealthShares(TM) ETFs are subject to increased risks associated with investing in a specific sector compared to a more diversified investment, as well as unique risks associated with the healthcare and biotechnology sector (i.e., government regulation, patent regulation, etc.).The prospectus is not an offer to buy or sell the portfolio shares, nor is the fund soliciting an offer to buy its shares in any jurisdiction where the offer or sale is not permitted. HealthShares(TM) Exchange Traded Funds are distributed by ALPS Distributors, Inc.
SOURCE HealthShares(TM) Inc.
Melissa Kanter of Edelman, +1-212-704-8261, melissa.kanter@edelman.com, forHealthShares(TM) Inc.
Copyright (C) 2007 PR Newswire. All rights reserved ********************************************************************** As of Sunday, 04-22-2007 23:59, the latest Comtex SmarTrend® Alert, an automated pattern recognition system, indicated an UPTREND on 03-26-2007 for DNDN @ $4.99. As of Sunday, 04-22-2007 23:59, the latest Comtex SmarTrend Alert, an automated pattern recognition system, indicated an UPTREND on 04-05-2007 for MRK @ $45.45. As of Sunday, 04-22-2007 23:59, the latest Comtex SmarTrend Alert, an automated pattern recognition system, indicated an UPTREND on 09-21-2006 for SRA @ $21.51. For more information on SmarTrend, contact your market data provider or go to SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright © 2004-2007 Comtex News Network, Inc. All rights reserved.
Production is for 9902B now
Which has been a great not-so-dry run for the real thing.
As long as Von E stays head of the FDA until 5/15, there is 100% chance of Provenge being approved since the 3/29 occurred the way it did.
Any one else believing different is either short, kidding themselves, or has inside information on a coup at the FDA.
DNDN held big in new HHJ etf...
http://finance.yahoo.com/q/bc?s=HHJ&t=3m&l=on&z=m&q=l&c=
Could you cite where that is from, who wrote it, etc?
See ya daytraders, bye, later....
The rest of us who know we own a $10B+ market cap stock whether it trades at $3.60 or $22 per share could care less about your RetroactiveBrokers.com claims to fame on DNDN.
Anyone ever seen so many "I've been in DNDN since..." posts from a bunch of April Flower Newbie posters on IV?
the lying mass of humanity is only exceeded on message boards by shill journalists and the hedge funds behind them....
IMCL missed Survival on Pancreatic
Good thing we got survival on prostate, eh?
Dendreon Sets 4/11 stockholders as voters at ASM
Item 8.01. Other Events.
Dendreon has set April 11, 2007 as the record date for stockholders who will be entitled to vote at Dendreon’s 2007 Annual Stockholders Meeting, which will be held on June 6, 2007.
10 AM AP NEWS - DR ROSENROSEN's CAREER DOWN IN FLAMES
AP
Out of the Gate: Dendreon Peaks Again
Monday April 9, 10:05 am ET
Dendreon Shares Gain Despite Analyst Warning About FDA Approval of Provenge
NEW YORK (AP) -- An analyst sounded a warning note on shares of biotechnology company Dendreon Corp. on Monday, which have more than tripled in value since March 30, but the stock continued to rise.
A Food and Drug Administration panel endorsed Provenge, a prostate cancer vaccine, on March 30, saying there was evidence the drug could be an effective cancer fighter. The agency usually follows panel recommendations in evaluating new drug applications.
ADVERTISEMENT
click here
Brean Murray Carret & Co. analyst Jonathan Aschoff said the FDA would set a "dangerous double standard" by approving Provenge, which did not meet its primary goal in two phase III trials. He said the FDA rejected Pharmacyclics Inc.'s new drug application for Xcytrin for not reaching its goals, but agreed to review the Provenge application.
Aschoff has "Sell" rating and a price target of $1.50 for shares of Seattle-based Dendreon, implying the stock will lose 91.7 percent of its value in the next year.
Five of the nine analysts reporting to Thomson Financial rate Dendreon stock at "Buy" or the equivalent. Two analysts rate it at "Neutral"-equivalent and two at "Sell"-equivalent.
Dendreon were up $2.32, or 12.9 percent, to $20.37 in morning trading on the Nasdaq Stock Market. The stock hit a new all-time high of $21 shortly after the open.
NBC: FDA Panel- citizen speaker Manarite's story
http://www.nbc-2.com/articles/readarticle.asp?articleid=11915&z=3&p=
Feuerstein Fires Back-Provenge 2 be approved
http://www.thestreet.com/_iwon/newsanalysis/biotech/10348030.html?cf=WSIWON111105
19 Job Openings-Bunch in NJ Manufacturing
Ramp it up.
http://www.resourcehire.com/clients/Dendreon/publicjobs/controller.cfm
headless is in the house
don't worry, I'll keep my volatile temperament (and I'll keep my volatile DNDN shares) to myself, just one post to say I'll be reading this board first for DNDN musings. IV is out of hand and will be for unforseeable future.
This is like when you favorite band goes from the 40 Watt Club to playing NFL stadiums.
I sold 1 kiloshare wed for possible legal inclusion reasons (and I was nervous as hell about Thurs and it soothed me somehow), but still hold long and strong 27 kiloshares. Not that it matters to anyone, but just wanted to say that not everyone is a DNDN trader, some of us know what we own, and know what it should be worth now given provenge approval, and it's a matter of principle as much as it is principal.
it always has been for me.
And thanks to those of you who chose not to bash Gold for your own personal therapeutic reasons when hedge funds destroyed your margin.
Carry on...